Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant.

Humans T-Lymphocytes Epstein-Barr Virus Infections / complications Transplantation, Homologous Treatment Outcome Herpesvirus 4, Human Graft vs Host Disease / etiology Hematopoietic Stem Cell Transplantation Stem Cell Transplantation Immunotherapy Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

Journal

American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369

Informations de publication

Date de publication:
01 2023
Historique:
received: 03 05 2022
accepted: 09 05 2022
pubmed: 14 5 2022
medline: 23 12 2022
entrez: 13 5 2022
Statut: ppublish

Résumé

We designed a trial to simultaneously address the problems of graft versus host disease (GVHD), infection, and recurrence of malignancy after allogeneic stem cell transplantation. CD34

Identifiants

DOI: 10.1002/ajh.26594 PMID: 35560045
pubmed: 35560045
doi: 10.1002/ajh.26594
doi:

Banques de données

ANZCTR
['ACTRN12618001090202']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

159-165

Informations de copyright

© 2022 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.

Références

Bone Marrow Transplant. 2012 May;47(5):706-15
pubmed: 21874063
J Clin Oncol. 2022 Feb 1;40(4):356-368
pubmed: 34855460
J Clin Invest. 2016 Sep 1;126(9):3363-76
pubmed: 27482888
N Engl J Med. 2016 Jan 7;374(1):43-53
pubmed: 26735993
J Clin Invest. 2016 Jun 1;126(6):2123-38
pubmed: 27111235
Blood. 2007 Dec 15;110(13):4552-9
pubmed: 17717135
Exp Hematol. 1999 Mar;27(3):561-8
pubmed: 10089920
Sci Transl Med. 2013 Feb 27;5(174):174ra27
pubmed: 23447018
J Clin Oncol. 2012 Sep 10;30(26):3194-201
pubmed: 22869882
Mol Ther. 2013 Nov;21(11):2113-21
pubmed: 23783429
Blood Adv. 2020 Jul 28;4(14):3443-3456
pubmed: 32722785
Cytotherapy. 2012 Jan;14(1):7-11
pubmed: 22172091
Am J Hematol. 2023 Jan;98(1):159-165
pubmed: 35560045
Blood. 2014 Dec 11;124(25):3817-27
pubmed: 25316679
Lancet. 2003 Oct 25;362(9393):1375-7
pubmed: 14585640
Blood. 2013 Dec 12;122(25):4129-39
pubmed: 24055823
Blood. 2010 Feb 4;115(5):925-35
pubmed: 19880495
J Clin Oncol. 2022 Apr 10;40(11):1174-1185
pubmed: 35007144
Transplantation. 2011 Nov 27;92(10):1077-84
pubmed: 22002347
Blood. 2021 May 13;137(19):2585-2597
pubmed: 33270816
Clin Cancer Res. 2019 Dec 15;25(24):7340-7350
pubmed: 31558475
N Engl J Med. 2012 Oct 18;367(16):1487-96
pubmed: 23075175
Nat Med. 2006 Sep;12(9):1039-47
pubmed: 16936725
Nat Med. 1996 May;2(5):551-5
pubmed: 8616714
Blood. 2021 Oct 21;138(16):1504-1509
pubmed: 34010392
Blood. 2013 May 2;121(18):3745-58
pubmed: 23435462
Blood. 2021 Apr 8;137(14):1970-1979
pubmed: 33512442

Auteurs

David J Gottlieb (DJ)

Blood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales.
Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales.
Department of Haematology, Westmead Hospital, Sydney, New South Wales.
T-Cell Therapies Group, Westmead Institute for Medical Research, Sydney, New South Wales.
ORCID: 0000-0001-5807-1766

Gaurav Sutrave (G)

Blood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales.
Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales.
T-Cell Therapies Group, Westmead Institute for Medical Research, Sydney, New South Wales.

Wei Jiang (W)

Blood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales.
Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales.

Selmir Avdic (S)

Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales.
T-Cell Therapies Group, Westmead Institute for Medical Research, Sydney, New South Wales.

Janine A Street (JA)

Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales.
T-Cell Therapies Group, Westmead Institute for Medical Research, Sydney, New South Wales.

Renee Simms (R)

Blood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales.
Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales.

Leighton E Clancy (LE)

Blood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales.
T-Cell Therapies Group, Westmead Institute for Medical Research, Sydney, New South Wales.
Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead, New South Wales, Australia.

Vicki Antonenas (V)

Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead, New South Wales, Australia.

Brian S Gloss (BS)

Westmead Research Hub, Westmead Institute for Medical Research, Sydney, New South Wales, Australia.

Caroline Bateman (C)

Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales.
T-Cell Therapies Group, Westmead Institute for Medical Research, Sydney, New South Wales.
Departments of Haematology and Oncology, Children's Hospital at Westmead, Sydney, New South Wales, Australia.

David C Bishop (DC)

Blood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales.
Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales.
T-Cell Therapies Group, Westmead Institute for Medical Research, Sydney, New South Wales.

Kenneth P Micklethwaite (KP)

Blood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales.
Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales.
Department of Haematology, Westmead Hospital, Sydney, New South Wales.
Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead, New South Wales, Australia.

Emily Blyth (E)

Blood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales.
Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales.
Department of Haematology, Westmead Hospital, Sydney, New South Wales.
T-Cell Therapies Group, Westmead Institute for Medical Research, Sydney, New South Wales.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Combining CD34+ stem cell selection with...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Combining CD34+ stem cell selection with...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus oncogènes › Infections à virus Epstein-Barr › Combining CD34+ stem cell selection with...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation homologue › Combining CD34+ stem cell selection with...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Combining CD34+ stem cell selection with...
questionsmedicales.fr › Virus › Virus oncogènes › Virus tumoraux à ADN › Gammaherpesvirinae › Lymphocryptovirus › Herpèsvirus humain de type 4 › Combining CD34+ stem cell selection with...
questionsmedicales.fr › Maladies du système immunitaire › Maladie du greffon contre l'hôte › Combining CD34+ stem cell selection with...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › Combining CD34+ stem cell selection with...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Combining CD34+ stem cell selection with...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Combining CD34+ stem cell selection with...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Leucémie lymphoïde › Leucémie-lymphome lymphoblastique à précurseurs B et T › Combining CD34+ stem cell selection with...